Unique ID issued by UMIN | UMIN000031186 |
---|---|
Receipt number | R000035604 |
Scientific Title | Comparison of MECHANISM of early and late vascular responses following treatment of ST-elevation Acute Myocardial Infarction with two different everolimus-eluting stents: Randomized controlled trial between biodegradable polymer and durable polymer stent |
Date of disclosure of the study information | 2018/02/15 |
Last modified on | 2023/08/24 11:54:36 |
Comparison of MECHANISM of early and late vascular responses following treatment of ST-elevation Acute Myocardial Infarction with two different everolimus-eluting stents: Randomized controlled trial between biodegradable polymer and durable polymer stent
MECHANISM-AMI-RCT
Comparison of MECHANISM of early and late vascular responses following treatment of ST-elevation Acute Myocardial Infarction with two different everolimus-eluting stents: Randomized controlled trial between biodegradable polymer and durable polymer stent
MECHANISM-AMI-RCT
Japan |
ST-elevation acute myocardial infarction (STEMI)
Cardiology |
Others
NO
To compare acute and late vascular responses to two different types of everolimus-etuting stents for the treatment of ST-elevation acute myocardial infarction evaluated by frequency domain optical coherence tomography
Bio-equivalence
Confirmatory
Pragmatic
Not applicable
strut coverage rate at two weeks
thrombus, dissection, incomplete stent apposition, target lesion revascularization, etc
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
YES
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Device,equipment |
durable polymer-based everolimus-etulint stent
biodegradable polymer-based everolimus-etulint stent
20 | years-old | <= |
85 | years-old | > |
Male and Female
Patients with
1)STEMI
2)Confirmation of coronary culprit lesion by angiography which need to be treated with drug-eluting stent
3)required cardiac catheterization after two weeks
Patients with
1)shock
2)left main disease
3)chronic kidney disease (serum Cr 2.0mg/dl)
4)cancer with life expectancy of less than 2 years
5)scheduled surgery within 3 months
120
1st name | Yoshihiro |
Middle name | |
Last name | Morino |
Iwate Medical University
Division of Cardiology
020-8505
19-1, Uchimaru, Morioka
019-651-5111
ymorino@iwate-med.ac.jp
1st name | Kanako |
Middle name | |
Last name | Omiya |
Iwate Medical University
Division of Cardiology
020-8505
19-1, Uchimaru, Morioka
019-651-5111
komoya@iwate-med.ac.jp
ARCHIMEDES Research Group
Boston Scientific
Profit organization
Japan
Iwate Medical University Certified Review Board
19-1, Uchimaru, Morioka
019-651-5111
hiroaki.kawamori@j.iwate-med.ac.jp
NO
岩手医科大学病院 他 約20施設
2018 | Year | 02 | Month | 15 | Day |
Unpublished
Completed
2019 | Year | 02 | Month | 15 | Day |
2018 | Year | 02 | Month | 14 | Day |
2018 | Year | 11 | Month | 22 | Day |
2021 | Year | 12 | Month | 31 | Day |
2018 | Year | 02 | Month | 07 | Day |
2023 | Year | 08 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000035604
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |